CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
The Theralymph project focuses on developing a novel gene therapy for lymphedema, a debilitating condition caused by fluid accumulation. By targeting lymphatic dysfunction through innovative gene delivery methods, it aims to improve the quality of life for individuals affected by this condition.
Lymphedema is a disabling condition induced by the accumulation of fluid and fat in the arm or in the leg.
It is an untreatable disease that affects 4 millions people in Europe and more than 120 millions people worldwide.
It is handicapping, painful and impacts substantially the quality of life.
In western countries, lymphedema is generally a consequence of cancer treatments i.e. ten to fifteen percent of women will develop lymphedema after breast cancer.
The main objective of Theralymph will be…
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Finland, HELSINGIN YLIOPISTO
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Switzerland, LAUSANNE
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Sweden, Uppsala
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Belgium, Bruxelles / Brussel
Type: Research institute
Activity type: Research Organisations
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
